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e have identified 10 barriers to overcome to conduct clinical translational 
research: 1) an idea, 2) interest/desire, 3) talent, 4) training, 5) time, 6) a team, 
7) regulatory support, 8) space, 9) money and 10) subjects or study partici-
pants. We discuss the essential elements in overcoming these barriers, including pro-
grams initiated at KUMC for training and conducting clinical translational research. 
We also discuss challenges related to organizing and running a multicenter investiga-
tor initiated trial. 
Spectrum of Translational Research 
Translational research has now been 
divided into at least four categories. T1 
research (Translation to Humans), in-
volves pre-clinical animal studies, first in 
human safety, tolerability and pharmaco-
kinetics studies. These first in human tri-
als are conducted first in a normal popu-
lation but often that is carried over into a 
population that the compound is target-
ing. The focus of this phase is discovery 
and safety. This corresponds to FDA 
Phase I trials.  
The T2 research (Translation to Pa-
tients) involves clinical trials that exam-
ine the effects of medication on a defined 
population. T2 research encompasses 
FDA categories of both Phase 2 and Phase 
3 trials. FDA defines Phase 2 trial as a trial 
in which preliminary efficacy data with 
additional safety data is obtained. This 
usually this study involves less than 100 
patients and depending on the popula-
tion can be a single site or a multicenter 
trial. FDA Phase 3 trials are classified as a 
pivotal efficacy trial. These trials are 
large and often multicenter. The focus in 
T2 research is both on safety and efficacy. 
T3 step is the Translation to Practice. 
The focus of T3 research is ‘getting the 
word out’ and putting that medication, 
procedure or behavioral intervention into 
practice, or implementation, dissemina-
tion and communication. In FDA terms, 
this is called post marketing Phase 4 re-
search.  
The next step is T4, Translation to 
Populations phase. These are usually 
community studies, policy studies and 
population outcome studies. The focus of 
this final phase is to improve population 
health. There is no FDA Phase equivalent 
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to T4 research. Finally, T5 research has 
sometimes been used to describe interna-
tional medical research. 
Translational science refers to the 
study of methods in order to do transla-
tional research. This is a new concept that 
the NIH is now emphasizing. For exam-
ple, comparing different types of recruit-
ment tools to see which is most effective 
would be considered translational sci-
ence. 
Barriers (and Essentials) to Clinical 
and Translation Research 
What barriers do investigators face 
in attempting to conduct clinical/transla-
tional research? We have identified 10 
barriers that investigators must over-
come for a successful study. In essence 
there are also essential strategies because 
if you do not have them, you cannot over-
come the barriers to initiate and conduct 
Clinical Translation Research (CTR). To 
do CTR, you must have 1) an idea, 2) in-
terest/desire, 3) talent, 4) training, 5) time, 
6) a team, 7) regulatory support, 8) space,
9) money and 10) subjects or study partic-
ipants.
Tools to overcome these barriers are 
available through multiple resources at 
medical centers, but the NIH/NCATS 
Clinical and Translational Science Award 
(CTSA) program is foremost in supplying 
these infrastructures to do CTR. At KU 
and in our Kansas City region our CTSA 
program is called Frontiers, the Heart-
land Institute for Clinical and Transla-
tional Research. 
We successfully overcame these bar-
riers in conducting several multi-center 
trials. We have recently coordinated and 
completed the following FDA Phase 2 
(T2) studies: 
• Therapeutic Trial of Mexiletine in Non-
Dystrophic Myotonia FDA-IND #
77,021(FDAOOPD – RO1-FD003454)1
• Safety and Tolerability Trial of Arimo-
clomol for Sporadic Inclusion Body Myo-
sitis FDA-IND # 76,7732
Figure 1: Spectrum of Translational Research 
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• Phase II Trial of Methotrexate in Myas-
thenia Gravis FDAIND #101,306
(FDAOOPD – RO1-FD003538)3 
• A Multi-Center Screening Trial of Safety
and Efficacy of Rasagiline in Subjects
with Amyotrophic Lateral Sclerosis
(ALS) FDA-IND 104,3604 
Only the mexiletine was a positive
trial showing a definite benefit of the 
drug, for muscle stiffness in patients with 
rare genetic sodium or chloride mutation. 
Even in trials which do not have a “posi-
tive” result in favor of the drug, we learn 
a great deal of information regarding the 
CTR process by performing such studies. 
It is essential to publish results of nega-
tive or indeterminate trials so that health 
caregivers and patients can be informed. 
By law, it is now required to enter all data 
on a trial when it is complete and in clin-
icaltrials.gov. It is required to register all 
trials in clinicaltrials.gov at the start of a 
study and then to put the final data 
online.  
We are currently coordinating the 
following multicenter trials: 
• Phase 2 Study of Rasagiline for Treat-
ment of Amyotrophic Lateral Sclerosis
FDA IND# 104,360 (FDAOOPD-R01-
FD003739)5
• Patient Assisted Intervention for Neu-
ropathy: Comparison of Treatment in
Real Life Situations (PAIN-CONTRoLS)
(CER-1306-02496) – a FDA Phase 4/T3
comparative effectiveness study.6
• Open Label study of subcutaneous immu-
noglobulin (SCIg) in myasthenia gravis
FDA-IND #: 15927 (Investigator Initi-
ated - Pharmaceutical funded)7
• Pilot Study of Acthar® Gel in Chronic
Inflammatory Demyelinating Neuropa-
thy FDA-IND #126318 (Investigator In-
itiated - Pharmaceutical funded) – no 
clinicaltrials.gov assigned yet 
• Phase II Study of Arimoclomol in IBM
FDA-IND # 76,773 (FDAOOPD-
RO1FD004809) – no clinicaltrials.gov
assigned yet
The funding agencies for these trials
have been the FDA Orphan Products Di-
vision (which funds rare disease re-
search), the new Patient Center for Out-
comes Research Institute (PCORI); and 
industry, through their investigator initi-
ated grant programs. Let’s examine the 
barriers mentioned above and how we 
overcame them. 
Barriers/Essentials to doing Multi-
Center Trials: Interest/Talent/ 
Time/Training 
Dr. Francis Collins, Director of the 
National Institutes of Health spoke at the 
Association for Clinical and Translational 
Science (ACTS) meeting in 2015. He re-
ported that there was a crisis in the num-
ber of physicians doing research. How do 
you convince young faculty to include re-
search in their career path and how do 
you train young physicians to conduct re-
search?  
The traditional MD/PhD pathway 
usually does not lead medical students to 
CTR and clinical trials. Rather these stu-
dents generally focus on early T1 labora-
tory research. We believe that MD/PhD 
programs should be modified so that the 
PhD can be obtained in CTR. This is cur-
rently being done at a few medical 
schools but it may be the best pathway to 
get a study early in their career to pursue 
CTR post residency. 
Currently in Frontiers, our NIH 
CTSA program, we do have a training 
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program (TL1) where a medical student 
takes a year between their first and sec-
ond year to do a CTR research project 
with a mentor and obtain a Master of Sci-
ence in Clinical Research. Our TL1 pro-
gram is open to Medical, Dental and 
Pharm D students but we have limited 
funds and train only four per year. To 
date we have had 16 students go through 
Frontiers TL1 program. Therefore, the 
number of students that can participate 
each year are few, but it does allow a se-
lective number of students their first 
foray into CTR. The MS-CR program is 33 
credit hours with the student thesis as the 
project. 
Unfortunately, historically much of 
the training for CTR has been on the job 
and occurs during fellowship or junior 
faculty years for MDs/DOs. Through 
Frontiers, we have designed a core of 16 
introductory lectures (Introduction to 
Clinical Research) that we encourage 
medical students, residents, fellows and 
PhD doctoral students to take. This is of-
fered every Thursday night in a 1.5 hr 
seminar each fall. For those interested in 
further education in CTR, they can take 
the courses that the TL-1 students take 
over a longer time, 1 or 2 courses a semes-
ter. They can therefore obtain their MS-
CR over 2 to 5 years. This is often done by 
junior faculty. 
There are some new CTR training ac-
tivities at NIH/NCATS. One has come 
through a CTSA grant, Enhancing Clini-
cal Research Professionals’ Training and 
Qualifications (ECRPTQ), in which Tom 
Shanley, MD and Richard Barohn, MD 
are PIs. As a result of the ECRPTQ effort, 
it is now recommended that all investiga-
tors and coordinators involved in clinical 
trials complete and pass online Good 
Clinical Practice (GCP) training. This will 
become the new floor for training investi-
gators and coordinators conducting tri-
als. In the second phase of this initiative 
competency requirements for conducting 
clinical trials are being developed and ad-
ditional training towards these compe-
tencies will be proposed. This process is 
expanding on an earlier joint task force 
on clinical trial competencies.8 In addi-
tion, the NCATS/CTSA Workforce Devel-
opment Task Force (Richard Barohn co-
chair), is starting to develop these new 
courses for clinical trials research, and 
other training modules including one for 
community-engaged research. 
As mentioned above, the majority of 
training that young investigators obtain 
is through on-the-job training. Usually 
the young faculty or student will have a 
senior clinical investigator to serve as a 
mentor and the training is accomplished 
through this mentorship. The following 
is an example from research project, 
Therapeutic Trial of Mexiletine in Non-
Dystrophic Myotonia. Jeff Statland MD 
became involved with Dr. Barohn on this 
project immediately following medical 
school and throughout his neurology res-
idency. This is unusual for a resident to 
be so actively involved in a multicenter 
clinical trial. Dr. Statland ended up be-
coming the first author of the paper pub-
lished in JAMA.9 He then did a NIH 
funded Clinical Neurotherapeutics T32 
Fellowship at the University of Rochester 
and he is now on faculty in the Depart-
ment of Neurology at KUMC where he is 
designing and implementing neuromus-
cular trials. He is a KL2 scholar on the 
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Frontiers CTSA NIH grant and he is men-
toring studies, fellows, residents and jun-
ior faculty on CTR.  
Additional barriers facing young in-
vestigators is finding time from clinical 
and teaching duties to participate in clin-
ical research. There is a salary discrep-
ancy between clinical income and income 
from research work. This is not a new 
problem. Dr. Francis Collins showed at 
the ACTS meeting in 2015 an article writ-
ten by him in 1991 regarding titled Physi-
cian-Scientists: A Vanishing Breed in 
which he talks about the vanishing re-
searcher and this income discrepancy.10 
Dr. Christopher Austin, Director of 
NCATS, frequently emphasizes that we 
need a way to train and maintain careers 
of all researchers, whether they be full 
time principal investigators or team play-
ers who do mainly clinical work but serve 
as co-investigators on trials. Analogies 
can be made to other fields, such as the 
quarterback and linebackers in football, 
or the conductor and 2nd violinist in a 
symphony, or the prima ballerina and 
sugar plum fairies in ballet. It is a chal-
lenge for both the leaders and essential 
team members to train and then remain 
involved in CTR. 
Barriers/Essentials to doing Multi-
Center Trials: Team Approach 
‘No man is an island, Entire of itself, 
Every man is a piece of the continent, A part 
of the main. If a clod be washed away by the 
sea, Europe is the less. As well as if a prom-
ontory were. As well as if a manor of thy 
friend's Or of thine own were: Any man's 
death diminishes me, Because I am involved 
in mankind, And therefore never send to 
know for whom the bell tolls; It tolls for thee’. 
– John Donne
A large team is required to conduct a 
clinical trial whether single site or multi-
site. Team members needed include but 
may not be limited to: principal investi-
gator, co-investigators for each site 
(blinded and unblinded), project man-
ager, study coordinators, clinical evalua-
tors, biostatisticians, data manager/infor-
matics, research pharmacy, labora-
tory/radiology personnel, budget/con-
tracts, Internal Review Board (IRB), Data 
Safety Monitoring Board (DSMB)/Safety 
Monitors, patient advocacy groups, pa-
tients (to serve on study design and im-
plementation committees) and external 
monitors. It is daunting to gather all of 
the team members, but just as daunting is 
coming up with the finances to pay for 
the team.  
Barriers/Essentials to doing Multi-
Center Trials: Sites on Team 
Another barrier that is essential to 
overcome is determining which sites will 
be members of the study team. Many 
clinical trials require multiple sites, espe-
cially in rare disease research (the focus 
of our research), in which recruitment is 
a challenge due to the rarity of patients. 
Those sites chosen will become the sites 
in the trial where patients will be enrolled 
and placed on the study drug and fol-
lowed throughout the study. As a leader 
of a multicenter trial, it is important to 
learn how to find and choose sites.  
On a current study that we are re-
cruiting for, Patient-Assisted Investiga-
tion of Neuropathic pain: Comparison of 
Treatments in Real-Life Situations, we 
need to utilize up to 40 sites to aid in re-
cruiting 400 patients with painful neu-
ropathy. Sites should be chosen based on 
if they have the patient population, and 
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whether their research team is willing to 
recruit. We are often asked how a PI in 
Kansas can find sites to ask to be in a trial. 
This is not an easy question to answer but 
predominantly this is due to networking 
through academic societies where one be-
comes familiar with investigators over 
time. A site may get in a study and can 
demonstrate how well they perform in 
recruitment and regulatory efforts and if 
they do well, they will be asked back to 
future studies.  
Another tool to aid in choosing sites 
is to become a member in a consortium. 
At KUMC, we currently are a member of 
the following consortia: Greater Plains 
Collaborative and the Vasculitis Patient 
Powered Research Network (both 
funded by PCORI), NeuroNEXT (funded 
by NIH), Alzheimer’s Disease Coopera-
tive Study (funded by NIA), Neurologi-
cal Emergencies Treatment Trials and the 
NIH StrokeNet Nation Clinical Coordi-
nating Center (both supported by 
NIH/NINDS). We are also a funded site 
of the National Cancer Institute. By be-
coming a member of a consortium, it al-
lows you to gain a foothold in conducting 
clinical trials. Your experience will be-
come a known commodity and more 
likely to be asked to participate in non-
consortium trials.  
Barriers/Essentials to doing Multi-
Center Trials: Regulatory 
A major barrier that must be over-
come is the handling of the regulatory is-
sues faced in every study. Most of the is-
sues are FDA regulatory issues. As the 
Principal Investigator (PI) at a site and 
the lead PI for the study, you are ulti-
mately responsible for what occurs at 
each site. You must follow FDA guide-
lines. For instance, do you need to apply 
for an Investigational New Drug applica-
tion or can you do the study under ex-
empt status? The rules for this are availa-
ble through the FDA.11 If you do apply for 
an IND, the FDA has to respond within 
30 days. If they do not respond in 30 days, 
you can proceed with the study. If they 
do respond, you will most likely need to 
modify the protocol per their request. In 
most cases acknowledgement from the 
FDA is required before submission to the 
IRB is allowed. If you obtain a FDA IND, 
you have to file an annual updated with 
the FDA. 
Another barrier that is essential to 
overcome is handling IRB approval from 
each site. Depending upon the study and 
the sites chosen to participate in the 
study, each site may have to submit to 
their own IRBs for approval. Recently 
there have been strides made in utilizing 
a single IRB on multicenter trials and 
there is a huge momentum at the NIH 
and PCORI levels to utilize a single IRB.12 
There are several proposed solutions to 
this barrier. First is to utilize a Central IRB 
(cIRB). This has been utilized in industry 
for some time with commercial central 
IRBS but academic centralized IRBs are 
new. cIRBs generally focus on particular 
topic or disease (e.g., NeuroNext, NCI 
CIRB). A second option could be utilize a 
commercial IRB (e.g. Western IRB). These 
are often used for industry-sponsored 
multi-center trials. A third option is to 
utilize an IRB Share agreement. This is a 
joint review model and “Shared Review 
Process” in which a lead IRB approves a 
study; the Local Oversight IRB verifies 
agreement with the determination of the 
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Lead IRB, and reviews local context is-
sues. The fourth option is to utilize a Re-
liance model. This is a single IRB of rec-
ord, chosen on a study-by-study basis, for 
the life of a study, involving a “reviewing 
IRB” and “relying institutions”. The 
PCORnet Greater Plains Collaborative 
utilizes this model.  
In a multicenter study the protocol 
must first be approved at the coordinat-
ing site, i.e. the IRB of record. Once it is 
approved, it is then sent to the other par-
ticipating sites. The IRB of record will 
need to approve the consent forms from 
the participating sites prior to site activa-
tion. Once the participating sites are acti-
vated, they may begin enrolling study 
participants. The primary site acting as 
the IRB of record will track annual IRB 
approvals and track all adverse events 
and serious adverse events at all sites. 
Barriers/Essentials to doing Multi-
center trials: Monitoring 
Pharmaceutical companies routinely 
do FDA compliant monitoring. This in-
volves having a monitor periodically go 
through the research files on subjects en-
rolled in studies to ensure all proper re-
search procedures are being followed. 
FDA released a White paper in 2007 titled 
The Food and Drug Administration’s 
Oversight of Clinical Trials (OEI-01-
00160) which found that investigators 
conducting investigator initiated studies 
were deficient at monitoring their stud-
ies.13 There has recently been a push by 
the FDA for investigator-initiated studies 
to monitor their studies. Since then, the 
FDA released a draft guidance in 2013 
that provides guidance for monitoring ti-
tled ‘Oversight of Clinical Investigations- 
A Risk-Based Approach to Monitoring’.14  
The barriers to monitoring include 
supporting the infrastructure to carry out 
the monitoring, which includes person-
nel and the finances to hire them. 
Whereas pharmaceutical companies have 
the financial resources to carry out moni-
toring, investigator initiated studies us-
ing federal or other funds do not. The 
budgets for investigator initiated studies 
rarely have the capacity to fund a robust 
monitoring program. What we have done 
in our studies is a compromise so that we 
do remote monitoring and have sites 
send a selected number of study records 
for review. If they are deficient, a higher 
level of monitoring can be activated. 
Barriers/Essentials to doing Multi-
center trials: Recruitment 
Frontiers Registry 
No investigator initiated study will 
succeed if you cannot recruit the subjects 
needed for the study, making this a major 
barrier. At the University of Kansas Med-
ical Center, we have arrived at some very 
innovative solutions. The Frontiers regis-
try was developed out of our NIH CTSA 
program. All patients seen in a KUMC 
clinic are asked to sign up so they can po-
tentially be contacted to be a research 
participant. As of January 2015, the Fron-
tiers Registry contains nearly 40,000 po-
tential research participants that were ac-
quired from 17 different participating 
KUMC clinics. Use of the Registry has 
continued to grow and has been used by 
49 different investigators (24 MDs and 25 
PhDs) for 64 different protocols, a 50% in-
crease over the last year. A variety of de-
partments are using the registry span-
ning KU-Wichita, KU-Lawrence and 
UMKC. A total of 14,051 contacts have 
been provided to investigators. Of these, 
22 
3423 were contacted by investigators re-
sulting in 188 participants enrolled in 
studies. This experience was recently 
published by Dr. Kluding and colleagues 
from Frontiers.15 
Pioneers 
Another solution we have developed 
is the Pioneers Community Research Re-
cruitment Registry, which also was de-
veloped in our NIH CTSA Frontiers pro-
gram. The Pioneers Community Research 
Recruitment Registry was launched in 
September 2013. The Pioneers registry is 
an online, community-based research 
participant registry that can be used by 
investigators from multiple institutions 
within the Frontiers network. There are 2 
primary objectives of the Pioneers Regis-
try program: 1) to provide a universal 
portal for anyone in the community to 
“Become a Pioneer” and agree to be con-
tacted for future research; 2) to provide 
an interactive website for listing studies 
that are actively recruiting participants. 
Investigators may utilize the Pioneers 
program not only to advertise their 
study, and to request names and contact 
information for potential research partic-
ipants using the results of a general med-
ical history survey, but they may also in-
clude an interactive “I am interested” 
button in the description of their study. 
This allows potential participants to con-
tact the study team directly, and may also 
include study-specific screening ques-
tions. These features were launched in 
Spring 2014 and are available to investi-
gators to support their recruitment ef-
forts. 
HERON 
The third solution is the Healthcare 
Enterprise Repository for Ontological 
Narration (HERON). HERON is a repos-
itory of de-identified clinical and bio-
medical data for clinical and translational 
research. HERON allows users to explore 
clinical data from multiple sources, 
housed in our EMR (Epic). Heron queries 
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can provide a count of how many pa-
tients at KUMC meet the criteria of a clin-
ical trial, and can provide additional pa-
tient observational data. HERON is 
linked to the Frontiers Research Partici-
pant Registry so that patients identified 
through HERON that participated in the 
registry can be contacted. 
Barriers/Essentials to doing Multi-
Center Trials: International Sites 
Conducting clinical trials within the 
border of the United States can be chal-
lenging. Adding sites outside of our bor-
der adds an additional layer of complex-
ity that few clinical investigators are 
aware of. For instance, if you have a site 
in Canada, you have to submit to Health 
Canada prior to the site initiating the 
trial. Health Canada is the Canadian ver-
sion of the FDA IND. There are differ-
ences in terminology that we face with 
the application. Also, there is additional 
paperwork few US clinical investigators 
know about when transporting drug 
across the border for research. This infor-
mation can be found at http://www.hc-
sc.gc.ca/dhp-mps/compli-conform/im-
port-export/gui-0084_biu-uif-eng.php.16 
Europe adds an additional barrier. 
There are European Union regulations 
that try to unify regulatory process for 
studies across Europe. However, each 
country often has their own additional re-
quirements. One of the most expensive 
barriers to using a site in Europe is the 
need to hire a Qualified Person (QP). This 
person is hired to inspect the locations 
where the drug is processed. For instance 
in our mexiletine study, the QP not only 
had to inspect the drug manufacturing 
plant in Israel, but also had to inspect 
where the drug and placebo were over-
encapsulated (University of Iowa’s Re-
search Pharmacy). There had to be sepa-
rate contracts with the pharmacy, data 
coordinating center, as well as with the 
University of Kansas Medical Center. 
Medication had to be shipped from the 
University of Iowa’s Research Pharmacy 
to a holding pharmacy where it had to be 
labeled. At that point, it could be shipped 
to the appropriate sites within Europe. 
Last but not least, customs at times would 
not release the drug pending a customs 
fee.  
Using international sites is expensive 
for a budget on an investigator initiated 
trial and this needs to be factored into the 
budget. On the other hand, these interna-
tional sites may be essential to meet en-
rollment needs for a study. We could not 
have completed our positive mexiletine 
in non-dystrophic myotonia study with-
out the partnering of the Institute of Neu-
rology in London, England, the Univer-
sity of Milan in Milan, Italy and Univer-
sity of Ontario in Canada.  
Conclusion 
There are significant barriers in car-
rying out a multicenter trial as the coor-
dinating site. These barriers can be over-
come but it takes personnel, infrastruc-
ture, time, training and money. Leading a 
multicenter study takes knowledge and 
skill and may not be for the timid or weak 
at heart. But the rewards are great and if 
you can overcome these many barriers 
discussed here, you and your team can 
have a significant impact in CTR and be-
come leaders in your field. 
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